Development of polysaccharide-coated layered double hydroxide nanocomposites for enhanced oral insulin delivery

Pang, Huiwen; Wu, Youzhi; Chen, Yang; Chen, Chen; Nie, Xuqiang; Li, Peng; Huang, Guojun; Xu, Zhi Ping; Han, Felicity Y.

doi:10.1007/s13346-023-01504-7

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This matrix not only shields drugs from degradation in the GIT but also enables controlled and sustained drug release. [28][29][30][31][32][33] This project aimed to create and assess oral delivery systems for T-20 using formulations grounded in PLGA and alginate.…”

Section: Introductionmentioning

confidence: 99%

Novel Delivery Systems for Oral Administration of Enfuvirtide: New Treatment Options for HIV/AIDS

Pang,

Qu,

Kumar

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Enfuvirtide (T‐20) is a synthetic peptide fusion inhibitor for the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). However, the peptide nature limits a wider application of T‐20 with subcutaneous injection (Fuzeon) the only available formulation. In this groundbreaking study, it is sought to overcome this limitation by employing poly lactic‐co‐glycolic acid (PLGA) and alginate to create novel oral delivery systems for T‐20. Remarkably, this investigation marks the first instance of assessing the efficacy of oral delivery systems in mice. Notably, both the PLGA and alginate formulations exhibit the capability to sustain T‐20 release, maintaining detectable levels in the bloodstream of mice for over 24 h after a single dose. By venturing into the realm of oral T‐20 delivery, this study opens avenues for the prospective development of oral formulations of T‐20, potentially leading to their evaluation in clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel Delivery Systems for Oral Administration of Enfuvirtide: New Treatment Options for HIV/AIDS

Pang,

Qu,

Kumar

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

Active packaging films based on the nanoform of chitin, alginate, and layered double hydroxides: characterization, mechanical properties, permeability, and bioactive properties

Hasanin,

Hassan,

Youssef

2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

Advances in Nanomedicine for Precision Insulin Delivery

Caturano,

Nilo,

Nilo

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Diabetes mellitus, which comprises a group of metabolic disorders affecting carbohydrate metabolism, is characterized by improper glucose utilization and excessive production, leading to hyperglycemia. The global prevalence of diabetes is rising, with projections indicating it will affect 783.2 million people by 2045. Insulin treatment is crucial, especially for type 1 diabetes, due to the lack of β-cell function. Intensive insulin therapy, involving multiple daily injections or continuous subcutaneous insulin infusion, has proven effective in reducing microvascular complications but poses a higher risk of severe hypoglycemia. Recent advancements in insulin formulations and delivery methods, such as ultra-rapid-acting analogs and inhaled insulin, offer potential benefits in terms of reducing hypoglycemia and improving glycemic control. However, the traditional subcutaneous injection method has drawbacks, including patient compliance issues and associated complications. Nanomedicine presents innovative solutions to these challenges, offering promising avenues for overcoming current drug limitations, enhancing cellular uptake, and improving pharmacokinetics and pharmacodynamics. Various nanocarriers, including liposomes, chitosan, and PLGA, provide protection against enzymatic degradation, improving drug stability and controlled release. These nanocarriers offer unique advantages, ranging from enhanced bioavailability and sustained release to specific targeting capabilities. While oral insulin delivery is being explored for better patient adherence and cost-effectiveness, other nanomedicine-based methods also show promise in improving delivery efficiency and patient outcomes. Safety concerns, including potential toxicity and immunogenicity issues, must be addressed, with the FDA providing guidance for the safe development of nanotechnology-based products. Future directions in nanomedicine will focus on creating next-generation nanocarriers with precise targeting, real-time monitoring, and stimuli-responsive features to optimize diabetes treatment outcomes and patient safety. This review delves into the current state of nanomedicine for insulin delivery, examining various types of nanocarriers and their mechanisms of action, and discussing the challenges and future directions in developing safe and effective nanomedicine-based therapies for diabetes management.

show abstract

Development of polysaccharide-coated layered double hydroxide nanocomposites for enhanced oral insulin delivery

Cited by 3 publications

References 43 publications

Novel Delivery Systems for Oral Administration of Enfuvirtide: New Treatment Options for HIV/AIDS

Novel Delivery Systems for Oral Administration of Enfuvirtide: New Treatment Options for HIV/AIDS

Active packaging films based on the nanoform of chitin, alginate, and layered double hydroxides: characterization, mechanical properties, permeability, and bioactive properties

Advances in Nanomedicine for Precision Insulin Delivery

Contact Info

Product

Resources

About